Compliance with Hepatitis B Vaccination Guidelines for Children and Adolescents Aged 3 to 17 in Germany from 2014 to 2017: Findings from a National Cross-Sectional Study - Top-Institutions - MDSpire

Compliance with Hepatitis B Vaccination Guidelines for Children and Adolescents Aged 3 to 17 in Germany from 2014 to 2017: Findings from a National Cross-Sectional Study

  • By

  • Sofie Gillesberg Lassen

  • Thomas Harder

  • Sandra Dudareva

  • Klaus Stark

  • Christina Poethko-Müller

  • January 16, 2026

  • 0 min

Share

Top Institutions in Gastroenterology

Brief introduction explaining scope and methodology.

  • #1

    Robert Koch Institute
    Robert Koch Institute

    Berlin, Germany

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Public Health

  • #2

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, Georgia

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Vaccinology

  • #3

    World Health Organization (WHO) Regional Office for Europe
    World Health Organization (WHO) Regional Office for Europe

    Copenhagen, Denmark

    Key Differentiators

    • Public Health
    • Infectious Diseases
    • Vaccination Policy

  • #4

    Karolinska Institutet
    Karolinska Institutet

    Stockholm, Sweden

    Key Differentiators

    • Infectious Diseases
    • Epidemiology
    • Vaccine Research

  • #5

    London School of Hygiene & Tropical Medicine
    London School of Hygiene & Tropical Medicine

    London, United Kingdom

    Key Differentiators

    • Public Health
    • Epidemiology
    • Infectious Diseases

Original Source(s)

Compliance with Hepatitis B Vaccination Guidelines for Children and Adolescents Aged 3 to 17 in Germany from 2014 to 2017: Findings from a National Cross-Sectional Study

  • by Sofie Gillesberg Lassen, Thomas Harder, Sandra Dudareva, Klaus Stark, Christina Poethko-Müller

  • January 16, 2026

Related Content

Advances in Hodgkin Lymphoma Treatment: Clinical Considerations for Managing Toxicities in Nivolumab-AVD Therapy

One of the most promising developments in advanced-stage Hodgkin lymphoma is the nivolumab-AVD regimen, which combines nivolumab with doxorubicin, vinblastine, and dacarbazine. This article provides practical knowledge for advanced practitioners to effectively manage the most common toxicities associated with nivolumab-AVD.

Gut microbiota and pediatric metabolic dysfunction–associated steatotic liver disease: clinical evidence and therapeutic implications

NLRP3 inflammasomes at the ARDS-cancer interface: mechanisms and translational hypotheses